Is Galecto, Inc. (GLTO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 0.8% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 0.8% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.4% / 33% | 82.7% / 33% | 5.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 0.8% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.4% / 33% | 82.7% / 33% | 5.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -109.5% | |
| Return on Assets (ROA) | -43.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $73,000 |
| Debt-to-Equity | 0.9 |
| Current Ratio | 3.7 |
| Total Assets | $17M |
Price & Trading
| Last Close | $28.91 |
| 50-Day MA | $26.48 |
| 200-Day MA | $14.12 |
| Avg Volume | 161K |
| Beta | 1.6 |
|
52-Week Range
$2.01
| |
About Galecto, Inc. (GLTO)
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Galecto, Inc. (GLTO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Galecto, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Galecto, Inc.'s debt ratio?
Galecto, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Galecto, Inc.'s key financial metrics?
Galecto, Inc. has a market capitalization of $1.7B. Return on equity stands at -109.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.